Last reviewed · How we verify
Endura
At a glance
| Generic name | Endura |
|---|---|
| Sponsor | Innovative Medical |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1) (PHASE3)
- The ESTxENDS Trial- Electronic Nicotine Delivery Systems as an Aid for Smoking Cessation-extension of Follow-up (NA)
- Efficacy and Safety of E-cigarettes for Smoking Cessation in Middle-aged Heavy Smokers (PHASE4)
- Venus-Vitae Pivotal Study Smart-Align Study (NA)
- Safety Study of the Use of Topical Cyclosporine in the Treatment of Dry Eye Disease (PHASE4)
- The Effects of Cyclosporin A in a Low Humidity Environment, on the Ocular Surface (NA)
- Will Restasis Eye Drops Increase Your Chance of Having a Successful Surgery? (NA)
- Topical Cyclosporine vs. Placebo for Epiphora Associated With Docetaxel (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Endura CI brief — competitive landscape report
- Endura updates RSS · CI watch RSS
- Innovative Medical portfolio CI